Latest news with #ZYUSLifeSciences
Associated Press
7 hours ago
- Business
- Associated Press
Brent H. Zettl Provides Update on Holdings of ZYUS Life Sciences Corporation
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Jun 27, 2025-- Mr. Brent H. Zettl (the ' acquiror '), who serves as the President and CEO and a director of ZYUS Life Sciences Corporation (' ZYUS ') provides updates to his holdings of Common shares (' Common Shares ') in the capital of ZYUS, Common Share purchase warrants of ZYUS (' Warrants ') and options to purchase Common Shares (' Options '). On June 27, 2025, the acquiror participated in a non-brokered private placement of units (' Units ') of ZYUS (the ' Private Placement ') at a price of $0.67 per Unit, with each Unit comprised of one Common Share and one half of one Warrant (each whole Warrant, a ' Private Placement Warrant '). Each Private Placement Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, subject to certain acceleration provisions. The acquiror acquired, indirectly through 1189115 B.C. LTD. 298,507 Units (comprised of 298,507 Common Shares and 149,253 Warrants) under the Private Placement. Immediately prior to the Private Placement, the acquiror owned, directly and indirectly, and exercised control over 33,730,573 Common Shares and 493,108 Options, representing 43.9% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 44.3% of ZYUS's issued and outstanding Common Shares on a partially diluted basis (assuming full exercise of all of the convertible securities held by the acquiror). Immediately following the Private Placement and as at the date hereof, the acquiror owns, directly and indirectly, and exercises control over 34,029,080 Common Shares, 149,253 Warrants and 493,108 Options, representing 43.9% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 44.3% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Following the Private Placement, the acquiror's securityholding percentage has decreased by 1.4% on an undiluted basis from the percentage held immediately following the September 2024 Event (as defined below) and by 5.4% on an undiluted basis from the percentage disclosed in the last early warning report filed by the acquiror on June 13, 2023 (the ' 2023 EWR '), and has decreased by 1.6% on a partially diluted basis from the acquiror's securityholding percentage held immediately following the September 2024 Event and by 6.1% on a partially diluted basis from the acquiror's securityholding percentage as at June 13, 2023. The acquiror's securityholding percentage on a partially diluted basis as disclosed in the 2023 EWR (51.68%) was stated in error. The correct securityholding percentage on a partially diluted basis as at June 13, 2023 was 50.5%. Since the completion of the acquisition of ZYUS Life Sciences Inc. by ZYUS in June 2023, the acquiror's securityholding percentage on a partially diluted basis has decreased from 50.5% to his securityholding percentage immediately prior to the Private Placement as a result of certain transactions and events, including the two following transactions which resulted in each case in a decrease in the acquiror's securityholding percentage by 2% or more since the prior event: (i) on July 31, 2024, the acquiror, disposed of 470,000 Common Shares held by 102042227 Saskatchewan Ltd. (' 102 Sask '), an entity controlled by the acquiror to in satisfaction of payments due in the aggregate amount of $432,400 (the ' July 2024 Event '); and (ii) on September 4, 2024,14,088 Warrants with an exercise price of $3.55 per Common Share previously issued to 102 Sask on March 4, 2022 expired unexercised (the ' September 2024 Event '). Immediately prior to the July 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 34,173,073 Common Shares, 292,933 Warrants and 493,108 Options, representing 48.2% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 48.8% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Immediately following the July 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 33,703,073 Common Shares, 292,933 Warrants and 493,108 Options, representing 47.6% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 48.1% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Immediately following the July 2024 Event, the acquiror's securityholding percentage has decreased by 1.7% on an undiluted basis from the acquiror's securityholding percentage as at June 13, 2023 as disclosed in the 2023 EWR and has decreased by 2.3% on a partially diluted basis from the acquior's securityholding percentage as at June 13, 2023 (which was 50.5%). Immediately prior to the September 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 33,703,073 Common Shares, 292,933 Warrants and 493,108 Options, representing 45.3% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 45.9% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Immediately following the September 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 33,703,073 Common Shares, 278,845 Warrants and 493,108 Options, representing 45.3% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 45.9% of ZYUS's issued and outstanding Common Shares on partially diluted basis. Following the September 2024 Event, the acquiror's securityholding percentage has decreased by 2.3% on an undiluted basis from the percentage held immediately following the July 2024 Event and has decreased by 2.2% on a partially diluted basis from the percentage held immediately following the July 2024 Event. The Acquiror's transactions were made for investment purposes. The acquiror may, from time to time and at any time, acquire additional securities of ZYUS in the open market or otherwise, and may dispose of any or all of securities of ZYUS in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the securities of ZYUS, the whole depending on market conditions, the business and prospects of ZYUS and other relevant factors. An early warning report will be filed by the Acquiror under applicable securities laws and will be available on ZYUS's SEDAR+ profile at For more information, please contact the Acquiror at 204-407 Downey Road, Saskatoon, SK S7N 4L8; telephone: (306) 242-2357 View source version on (306) 242-2357 KEYWORD: NORTH AMERICA CANADA INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY SOURCE: ZYUS Life Sciences Corporation Copyright Business Wire 2025. PUB: 06/27/2025 10:53 PM/DISC: 06/27/2025 10:53 PM
National Post
11 hours ago
- Business
- National Post
Brent H. Zettl Provides Update on Holdings of ZYUS Life Sciences Corporation
Article content This press release is issued pursuant to the requirements of National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues Article content SASKATOON, Saskatchewan — Mr. Brent H. Zettl (the ' acquiror '), who serves as the President and CEO and a director of ZYUS Life Sciences Corporation (' ZYUS ') provides updates to his holdings of Common shares (' Common Shares ') in the capital of ZYUS, Common Share purchase warrants of ZYUS (' Warrants ') and options to purchase Common Shares (' Options '). Article content On June 27, 2025, the acquiror participated in a non-brokered private placement of units (' Units ') of ZYUS (the ' Private Placement ') at a price of $0.67 per Unit, with each Unit comprised of one Common Share and one half of one Warrant (each whole Warrant, a ' Private Placement Warrant '). Each Private Placement Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, subject to certain acceleration provisions. The acquiror acquired, indirectly through 1189115 B.C. LTD. 298,507 Units (comprised of 298,507 Common Shares and 149,253 Warrants) under the Private Placement. Article content Immediately prior to the Private Placement, the acquiror owned, directly and indirectly, and exercised control over 33,730,573 Common Shares and 493,108 Options, representing 43.9% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 44.3% of ZYUS's issued and outstanding Common Shares on a partially diluted basis (assuming full exercise of all of the convertible securities held by the acquiror). Immediately following the Private Placement and as at the date hereof, the acquiror owns, directly and indirectly, and exercises control over 34,029,080 Common Shares, 149,253 Warrants and 493,108 Options, representing 43.9% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 44.3% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Following the Private Placement, the acquiror's securityholding percentage has decreased by 1.4% on an undiluted basis from the percentage held immediately following the September 2024 Event (as defined below) and by 5.4% on an undiluted basis from the percentage disclosed in the last early warning report filed by the acquiror on June 13, 2023 (the ' 2023 EWR '), and has decreased by 1.6% on a partially diluted basis from the acquiror's securityholding percentage held immediately following the September 2024 Event and by 6.1% on a partially diluted basis from the acquiror's securityholding percentage as at June 13, 2023. The acquiror's securityholding percentage on a partially diluted basis as disclosed in the 2023 EWR (51.68%) was stated in error. The correct securityholding percentage on a partially diluted basis as at June 13, 2023 was 50.5%. Article content Since the completion of the acquisition of ZYUS Life Sciences Inc. by ZYUS in June 2023, the acquiror's securityholding percentage on a partially diluted basis has decreased from 50.5% to his securityholding percentage immediately prior to the Private Placement as a result of certain transactions and events, including the two following transactions which resulted in each case in a decrease in the acquiror's securityholding percentage by 2% or more since the prior event: (i) on July 31, 2024, the acquiror, disposed of 470,000 Common Shares held by 102042227 Saskatchewan Ltd. (' 102 Sask '), an entity controlled by the acquiror to in satisfaction of payments due in the aggregate amount of $432,400 (the ' July 2024 Event '); and (ii) on September 4, 2024,14,088 Warrants with an exercise price of $3.55 per Common Share previously issued to 102 Sask on March 4, 2022 expired unexercised (the ' September 2024 Event '). Immediately prior to the July 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 34,173,073 Common Shares, 292,933 Warrants and 493,108 Options, representing 48.2% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 48.8% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Immediately following the July 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 33,703,073 Common Shares, 292,933 Warrants and 493,108 Options, representing 47.6% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 48.1% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Immediately following the July 2024 Event, the acquiror's securityholding percentage has decreased by 1.7% on an undiluted basis from the acquiror's securityholding percentage as at June 13, 2023 as disclosed in the 2023 EWR and has decreased by 2.3% on a partially diluted basis from the acquior's securityholding percentage as at June 13, 2023 (which was 50.5%). Immediately prior to the September 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 33,703,073 Common Shares, 292,933 Warrants and 493,108 Options, representing 45.3% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 45.9% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Immediately following the September 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 33,703,073 Common Shares, 278,845 Warrants and 493,108 Options, representing 45.3% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 45.9% of ZYUS's issued and outstanding Common Shares on partially diluted basis. Following the September 2024 Event, the acquiror's securityholding percentage has decreased by 2.3% on an undiluted basis from the percentage held immediately following the July 2024 Event and has decreased by 2.2% on a partially diluted basis from the percentage held immediately following the July 2024 Event. Article content The Acquiror's transactions were made for investment purposes. The acquiror may, from time to time and at any time, acquire additional securities of ZYUS in the open market or otherwise, and may dispose of any or all of securities of ZYUS in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the securities of ZYUS, the whole depending on market conditions, the business and prospects of ZYUS and other relevant factors. Article content Article content Article content Article content Article content
National Post
16-05-2025
- Business
- National Post
ZYUS Life Sciences Announces Closing of Unit Offering
Article content Article content SASKATOON, Saskatchewan — ZYUS Life Sciences Corporation (the ' Company ') (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that, further to its press releases dated May 1 and May 6, 2025, it has closed the second and final tranche (the ' Second Tranche ') of its non-brokered private placement (the ' Offering ') of units of the Company (each a ' Unit ') through the issuance of a further 871,212 Units for gross proceeds of $574,999.92. The aggregate gross proceeds raised in the Second Tranche and first tranche of the Offering (which closed on May 6, 2025) (the ' First Tranche ') is approximately $1.37 million. The Company issued a total of 2,083,333 Units each priced at $0.66 per Unit in the Offering. Each Unit consists of one common share of the Company (a ' Common Share ') and one-half of one Common Share purchase warrant (each whole Common Share purchase warrant, a ' Warrant '), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.94 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms. Proceeds of the Offering will be used for general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. Article content The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring September 7, 2025 and all securities issued under the Second Tranche are subject to a hold period expiring September 16, 2025, in accordance with applicable securities laws and the policies of the TSX Venture Exchange (the ' TSXV '). The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. Article content The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the ' U.S. Securities Act '), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. Article content ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Article content This news release contains 'forward-looking information' within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, receipt of TSXV final acceptance and use of proceeds from the Private Placement. Any such forward-looking statements may be identified by words such as 'expects', 'anticipates', 'intends', 'contemplates', 'believes', 'projects', 'plans', 'will' and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, the Company's ability to obtain TSXV final acceptance and use of proceeds from the Private Placement are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Article content Article content Article content Article content Article content Contacts Article content Article content Article content
